<SEC-DOCUMENT>0001104659-22-100639.txt : 20220916
<SEC-HEADER>0001104659-22-100639.hdr.sgml : 20220916
<ACCEPTANCE-DATETIME>20220916073344
ACCESSION NUMBER:		0001104659-22-100639
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20220916
FILED AS OF DATE:		20220916
DATE AS OF CHANGE:		20220916

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bioceres Crop Solutions Corp.
		CENTRAL INDEX KEY:			0001769484
		STANDARD INDUSTRIAL CLASSIFICATION:	AGRICULTURE CHEMICALS [2870]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38836
		FILM NUMBER:		221246970

	BUSINESS ADDRESS:	
		STREET 1:		PO BOX 309, UGLAND HOUSE
		CITY:			GEORGE TOWN, GRAND CAYMAN
		STATE:			E9
		ZIP:			KY1-1104
		BUSINESS PHONE:		54 341 486 1122

	MAIL ADDRESS:	
		STREET 1:		OCAMPO 210 BIS, PREDIO CCT
		CITY:			ROSARIO
		STATE:			C1
		ZIP:			2000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tm2225993d1_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Report of Foreign Private Issuer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Rules&nbsp;13a-16 or 15d-16 under</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the month of September&nbsp;2022</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-38836</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>BIOCERES CROP
SOLUTIONS CORP.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ocampo 210 bis, Predio CCT, Rosario</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Province of Santa Fe, Argentina</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover Form&nbsp;20-F or Form&nbsp;40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form&nbsp;20-F&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Form&nbsp;40-F&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K
in paper as permitted by Regulation S-T Rule&nbsp;101(b)(1): <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K
in paper as permitted by Regulation S-T Rule&nbsp;101(b)(7): <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BIOCERES CROP SOLUTIONS HAS ENTERED INTO A
LONG-TERM AGREEMENT WITH SYNGENTA FOR THE DEVELOPMENT AND COMMERCIALIZATION OF BIOLOGICAL SEEDCARE SOLUTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Bioceres Crop Solutions Corp. (NASDAQ: BIOX) (&ldquo;Bioceres&rdquo;)
has entered into a 10-year agreement with Syngenta Seedcare (&ldquo;Syngenta&rdquo;), under which Syngenta will become the exclusive
global distributor of Bioceres&rsquo; biological solutions for seed care applications. The agreement covers nitrogen-fixing Rhizobia
seed treatment solutions, and other biological seed treatment solutions currently in the portfolio or pipeline of Rizobacter. The products
in the agreement will be sold under the trademarks owned by Bioceres or its Affiliates. Third party or private labels will be discussed
on a case-by-case basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ProFarm Group&rsquo;s (formerly Marrone Bio Innovations) biological
solutions are not included in scope of the current agreement. Bioceres retains global rights for use on HB4&reg; crops and, in the United
States, Syngenta rights will be non-exclusive with respect to certain customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The exclusive commercial collaboration is global, except for Argentina
where both parties will continue to work under the existing framework. Implementation will be staggered, commencing in 2023, and subject
to regulatory clearances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The agreement establishes a joint R&amp;D program to accelerate the
development and registration of Bioceres&rsquo; Pipeline Products and new solutions for seed treatment, foliar and other applications,
globally. Funding for R&amp;D platform will be shared, with Syngenta funding at 70% for selected Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In consideration of the rights granted to
Syngenta under the distribution agreement and the R&amp;D collaboration, Syngenta will make an upfront payment of $50 million to
Bioceres. For the duration of the agreement, Bioceres will receive 50% to 30% of the profits generated by sales conducted by
Syngenta, depending on the geography and the year. The agreement sets global minimum targets for profits to be received by Bioceres,
in order for Syngenta to retain its exclusive rights. Syngenta will cover all operating expenses incurred in connection with the
marketing and sale in exclusive territory. Bioceres&rsquo; subsidiary Rizobacter will act as the exclusive supplier to Syngenta for
products under the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-looking statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This communication includes &ldquo;forward-looking statements&rdquo;
within the meaning of the &ldquo;safe harbor&rdquo; provisions of the United States Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by the use of words such as &ldquo;forecast,&rdquo; &ldquo;intend,&rdquo; &ldquo;seek,&rdquo;
 &ldquo;target,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;expect,&rdquo; &ldquo;estimate,&rdquo; &ldquo;plan,&rdquo;
 &ldquo;outlook,&rdquo; and &ldquo;project&rdquo; and other similar expressions that predict or indicate future events or trends or that
are not statements of historical matters. Such forward-looking statements are based on management&rsquo;s reasonable current assumptions,
expectations, plans and forecasts regarding the Company&rsquo;s current or future results and future business and economic conditions
more generally. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, levels
of activity, performance or achievement of the Company to be materially different from any future results expressed or implied by such
forward-looking statements, and there can be no assurance that actual results will not differ materially from management&rsquo;s expectations
or could affect the Company&rsquo;s ability to achieve its strategic goals, including the uncertainties relating to the impact of COVID-19
on the Company&rsquo;s business, operations, liquidity and financial results and the other factors that are described in the sections
entitled &ldquo;Risk Factors&rdquo; in the Company's Securities and Exchange Commission filings updated from time to time. The preceding
list is not intended to be an exhaustive list of all of our forward-looking statements. Therefore, you should not rely on any of these
forward-looking statements as predictions of future events. All forward-looking statements contained in this release are qualified in
their entirety by this cautionary statement. Forward-looking statements speak only as of the date they are or were made, and the Company
does not intend to update or otherwise revise the forward-looking statements to reflect events or circumstances after the date of this
release or to reflect the occurrence of unanticipated events, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit&nbsp;List</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 8%"><B>Exhibit&nbsp;No.</B></TD>
    <TD STYLE="padding-bottom: 1pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 91%"><B>Description</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><A HREF="tm2225993d1_ex99-1.htm">99.1</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="tm2225993d1_ex99-1.htm">Press release, Bioceres Crop Solutions Corp. announces strategic collaboration with Syngenta</A></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">BIOCERES CROP SOLUTIONS CORP.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">(Registrant)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 40%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Dated: September&nbsp;16, 2022</TD>
    <TD>By:</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: black 1pt solid">/s/ Federico Trucco</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name: </TD>
    <TD>Federico Trucco</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2225993d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-size: 10pt; color: Black"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Media Release</B></FONT></TD><TD STYLE="width: 25%; text-align: left"><FONT STYLE="font-size: 10pt; color: Black"><B>Syngenta
                                            AG</B></FONT></TD><TD STYLE="text-align: justify; width: 25%"><FONT STYLE="font-size: 10pt; color: Black"><B>Bioceres Crop Solutions</B></FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt; color: Black">Rosentalstrasse 67</FONT></TD><TD STYLE="text-align: justify">Ocampo 210 bis, Predio CCT</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">4002 Basel, Switzerland</TD><TD STYLE="text-align: justify">Rosario 2000, Argentina</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">www.syngenta.com</TD><TD STYLE="text-align: justify">www.biocerescrops.com</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; color: #00a0be"><FONT STYLE="font-size: 10pt; color: Black"><B>Syngenta
Seedcare and Bioceres Crop Solutions collaborate to bring innovative biological seed treatments to market</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #626469"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&bull;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Syngenta
                                            Seedcare to become the exclusive commercialization distributor of Bioceres&rsquo;s biological
                                            seed treatment solutions globally</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #626469"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&bull;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Long-term
                                            R&amp;D collaboration to accelerate global registration of existing products and joint development
                                            of new biological solutions</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: #626469"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&bull;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Agreement
                                            brings together the world&rsquo;s leading seed treatment business with a leader in biological
                                            crop productivity solutions</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: #626469"><FONT STYLE="font-size: 10pt; color: Black"><B>Basel,
Switzerland / Rosario, Argentina, September&nbsp;16, 2022 &ndash; </B>Customers seeking cutting-edge biological seed treatment solutions
will benefit from a global commercial and R&amp;D collaboration announced today between Syngenta Crop Protection&rsquo;s Seedcare business
and Bioceres Crop Solutions (NASDAQ: BIOX), a leader in biological crop productivity solutions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: #626469"><FONT STYLE="font-size: 10pt; color: Black">Bioceres
is a key provider of biological inoculants, including rhizobia bacteria, which improve crop nutrition and support plant growth. This
seed-applied solution helps crops, such as soybean, capture nitrogen from the atmosphere and significantly reduces the need for nitrogen
fertilizers &ndash; supporting regenerative agriculture. Biological seed treatment products such as inoculants, biocontrols and biostimulants
are based on microorganisms, their metabolites, plant extracts and other naturally occurring materials. The global biologicals seeds
treatment market is projected to grow from $0.6bn in 2020 to $1.6bn by 2030.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: #626469"><FONT STYLE="font-size: 10pt; color: Black">The
collaboration between Bioceres and Syngenta builds on a successful commercial partnership of more than 20 years in Argentina. Under the
agreement*, Syngenta Seedcare will become the exclusive global commercialization distributor for Bioceres&rsquo; biological seed treatment
solutions, except in Argentina where they will continue to collaborate under the existing framework. Under the long-term R&amp;D collaboration,
the companies will jointly undertake the development of new products while accelerating the registration of products already in the pipeline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: #626469"><FONT STYLE="font-size: 10pt; color: Black">Jonathan
Brown, Global Head of Syngenta Seedcare said, &ldquo;The agreement with Bioceres furthers our strategy to provide growers with more complementary
choices to manage pest resistance and improve crop health. We draw strengths from our longstanding relationship with Bioceres and are
fully committed to providing growers with more sustainable innovations to further improve seed health.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt; color: Black"><IMG SRC="tm2225993d1_ex99-1img001.jpg" ALT="" STYLE="height: 119px; width: 850px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: #626469"><FONT STYLE="font-size: 10pt; color: Black">&ldquo;This
announcement shows the value of our commercial offerings and R&amp;D capabilities, and greatly expands and accelerates our ability to
reach more growers through the global reach of Syngenta Seedcare,&rdquo; said Chief Executive Officer of Bioceres Federico Trucco. &ldquo;Biological
products play an important role in offering growers new solutions to increase crop yields while reducing agriculture&rsquo;s environmental
footprint. We believe this collaboration with Syngenta will allow us both to advance those goals more rapidly in a time of significant
global need for new solutions.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: #626469"><FONT STYLE="font-size: 10pt; color: Black">Syngenta
Seedcare and Bioceres will expand their cooperation in key markets such as Brazil and China, as well as in other regions around the world.
Implementation of the agreement will be subject to regulatory clearances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt; color: Black"><I>*Bioceres
will retain global rights to use its biologicals solutions on HB4&reg; crops, which have been modified to better withstand drought events.
The portfolio of Marrone Bio Innovations, recently acquired by Bioceres and commercialized by ProFarm Group, one of Bioceres&rsquo; main
subsidiaries is also outside the scope of the current agreement.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; font-size: 10pt"><IMG SRC="tm2225993d1_ex99-1img002.jpg" ALT=""></TD>
    <TD STYLE="width: 80%"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt; color: Black"><B>About Syngenta</B></FONT></P>
                                                                      <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                      <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt; color: Black">Syngenta
                                            is one of the world&rsquo;s leading agriculture companies, comprised of Syngenta Crop Protection
                                            and Syngenta Seeds. Our ambition is to help safely feed the world while taking care of the
                                            planet. We aim to improve the sustainability, quality and safety of agriculture with world
                                            class science and innovative crop solutions. Our technologies enable millions of farmers
                                            around the world to make better use of limited agricultural resources. Syngenta Crop Protection
                                            and Syngenta Seeds are part of Syngenta Group. In more than 100 countries we are working
                                            to transform how crops are grown. Through partnerships, collaboration and The Good Growth
                                            Plan we are committed to accelerating innovation for farmers and nature, striving for regenerative
                                            agriculture, helping people stay safe and healthy and partnering for impact. To learn more
                                            visit <U>www.syngenta.com</U> and <U>www.goodgrowthplan.com</U>. Follow us on Twitter at
                                            <U>www.twitter.com/Syngenta</U>, <U>www.twitter.com/SyngentaUS</U> and on LinkedIn at <U>www.linkedin.com/company/syngenta</U></FONT></P></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><IMG SRC="tm2225993d1_ex99-1img003.jpg" ALT="Logo, company name&#10;&#10;Description automatically generated" STYLE="height: 65px; width: 80px"></FONT></TD>
    <TD STYLE="width: 80%"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt; color: Black"><B>About Bioceres Crop
                           Solutions Corp.</B></FONT></P>
                                                                      <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                      <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt; color: Black">Bioceres
                                            Crop Solutions Corp. (NASDAQ: BIOX) is a fully integrated provider of crop productivity technologies
                                            designed to enable the transition of agriculture towards carbon neutrality. To do this, Bioceres&rsquo;
                                            solutions create economic incentives for farmers and other stakeholders to adopt environmentally
                                            friendlier production practices. The Company has a unique biotech platform with high-impact,
                                            patented technologies for seeds and microbial ag-inputs, as well as next generation crop
                                            nutrition and protection solutions. Through its HB4 program, the Company is bringing digital
                                            solutions to support growers&rsquo; decisions and provide end-to-end traceability for production
                                            outputs. For more information, visit&nbsp;<U>here</U>. &nbsp;</FONT></P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #626469"><FONT STYLE="font-size: 10pt; color: Black"><B><U>Contact
Information</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #626469"><FONT STYLE="font-size: 10pt; color: Black"><B>Syngenta
Crop Protection</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #626469"><FONT STYLE="font-size: 10pt; color: Black">Michelle
Ng</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #626469"><FONT STYLE="font-size: 10pt; color: Black">Head,
External Communications</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: blue"><FONT STYLE="font-size: 10pt; color: Black"><U>michelle.ng@syngenta.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #626469"><FONT STYLE="font-size: 10pt; color: Black"><B>Bioceres
Crop Solutions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #626469"><FONT STYLE="font-size: 10pt; color: Black">Paula
Savanti</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #626469"><FONT STYLE="font-size: 10pt; color: Black">Investor
Relations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: blue"><FONT STYLE="font-size: 10pt; color: Black"><U>investorrelations@biocerescrops.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">Data protection is important
to us. You are receiving this publication on the legal basis of Article&nbsp;6 para 1 lit. f GDPR (&ldquo;legitimate interest&rdquo;).
However, if you do not wish to receive further information about Syngenta, just send us a brief informal <U>message</U> and we will no
longer process your details for this purpose. You can also find further details in our <U>privacy statement</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #626469"><FONT STYLE="font-size: 10pt; color: Black"><B><I>Cautionary
Statement Regarding Forward-Looking Statements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #626469"><FONT STYLE="font-size: 10pt; color: Black">This document
may contain forward-looking statements, which can be identified by terminology such as &lsquo;expect&rsquo;, &lsquo;would&rsquo;, &lsquo;will&rsquo;,
 &lsquo;potential&rsquo;, &lsquo;plans&rsquo;, &lsquo;prospects&rsquo;, &lsquo;estimated&rsquo;, &lsquo;aiming&rsquo;, &lsquo;on track&rsquo;
and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially
from these statements. For Syngenta, such risks and uncertainties include risks relating to legal proceedings, regulatory approvals,
new product development, increasing competition, customer credit risk, general economic and market conditions, compliance and remediation,
intellectual property rights, implementation of organizational changes, impairment of intangible assets, consumer perceptions of genetically
modified crops and organisms or crop protection chemicals, climatic variations, fluctuations in exchange rates and/or commodity prices,
single source supply arrangements, political uncertainty, natural disasters, and breaches of data security or other disruptions of information
technology. Syngenta assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other
factors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #626469"><FONT STYLE="font-size: 10pt; color: Black">&copy;2022
Syngenta. Rosentalstrasse 67, 4058 Basel, Switzerland.</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt; color: Black">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2225993d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2225993d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !_ XH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[2?=_>RQ]OO/^?N?_OX:/M]Y_P _<_\ W\-5Z*.5=@]I/N_O98^WWG_/W/\
M]_#1]OO/^?N?_OX:KT4<J[![2?=_>RQ]OO/^?N?_ +^&C[?>?\_<_P#W\-5Z
M*.5=@]I/N_O98^WWG_/W/_W\-'V^\_Y^Y_\ OX:KT4<J[![2?=_>RQ]OO/\
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M#VD^[^]EC[?>?\_<_P#W\-'V^\_Y^Y_^_AJO11RKL'M)]W][+'V^\_Y^Y_\
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MWT(K-K2,E)73,)TY4Y<LU9A1113("BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBC!QGM0 4444 ;=EJ\,7AB\T=T97GG202#I@$9!_+-
M=FFJ:9-\08[DWMO]CM;#;%*9!M!SC&?7YC7F-%83H1E?7>_XV_R.ZCCYTTE9
M.UOPNTOO9Z%KGBS3=-TZ?3M (EEN"QGN2#U;J<]V.>O05Y[115TJ4::LC+$X
MJ>(DG+1+9+9!1116AS!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP3[ _P ZQPTO8UG&7H=F8TUC,&JM-:Z-?DU_78/AOI?V31)+YUQ)=OQG^XO
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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H@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm2225993d1_ex99-1img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2225993d1_ex99-1img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  C '8# 2(  A$! Q$!_\0
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MI.K6\9W1K*"A\OA@21D$?R%95<-6=.\5_P ,<N,56=/EHNS.C^&7VS4M2O\
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,% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>tm2225993d1_ex99-1img003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2225993d1_ex99-1img003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !! % # 2(  A$! Q$!_\0
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AR'#_ ->P_P#0JNT454NA$.OJ%%%%26%%%% !1110!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
